drugset / Trial / NCT06004336
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Phase 2
Recruiting
144 enrolled
M.D. Anderson Cancer Center
Cancer Prevention Research Institute of Texas · collabMerck Sharp & Dohme LLC · collab
RandomizedSingle-groupSingle-blindTreatment
Summary
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Timeline
- Start
- 2023-10-31
- Primary completion
- 2029-01-01
- Completion
- 2029-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |